` BD1 (BARD1 Life Sciences Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

BD1
vs
S&P/ASX 300

Over the past 12 months, BD1 has underperformed S&P/ASX 300, delivering a return of 0% compared to the S&P/ASX 300's 10% growth.

Stocks Performance
BD1 vs S&P/ASX 300

Loading
BD1
S&P/ASX 300
Add Stock
www.alphaspread.com

Performance Gap
BD1 vs S&P/ASX 300

Loading
BD1
S&P/ASX 300
Difference
www.alphaspread.com

Performance By Year
BD1 vs S&P/ASX 300

Loading
BD1
S&P/ASX 300
Add Stock

Competitors Performance
BARD1 Life Sciences Ltd vs Peers

BARD1 Life Sciences Ltd
Glance View

Market Cap
83.3m AUD
Industry
Health Care

BARD1 Life Sciences Ltd. is a biotechnology company, which engages in the provision of medical services. The firm is engaged in research, development, and commercialization of non-invasive diagnostic products for the early detection of cancer. The Company’s technologies include BARD1, SubB2, NET and hTERT. BARD1 is a biomarker platform covering various tumor markers including nucleic acids, proteins, and autoantibodies for early cancer diagnosis.SubB2M is a pan-cancer probe for monitoring cancer treatment response and recurrence across a wide range of cancers. NET is designed to capture and purify biomarkers, including acids, cells, and exosomes. hTERT is an antibody-based assay to detect hTERT, a component of telomerase, in cells.

BD1 Intrinsic Value
Not Available
Back to Top